Brilique

ticagrelor

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Brilique. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Brilique.

What is Brilique?

Brilique is a medicine that contains the active substance ticagrelor. It is available as tablets (60 and 90 mg).

What is Brilique used for?

Brilique is used together with aspirin (acetylsalicylic acid) to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) such as heart attacks or strokes. It is used in adults with acute coronary syndrome, a group of conditions in which blood flow in the vessels supplying the heart is blocked so heart tissue cannot work properly or dies, and which includes heart attack and unstable angina (a severe type of chest pain). Brilique is also used in adults who had a heart attack a year or more ago and are at a high risk of an atherothrombotic event.

The medicine can only be obtained with a prescription.

How is Brilique used?

For patients with acute coronary syndrome, the starting dose of Brilique is two 90-mg tablets taken at once, followed by a regular dose of one 90-mg tablet twice a day. They should take Brilique for a year unless the doctor asks them to stop it earlier. For longer treatment, the dose of Brilique should be reduced to one 60-mg tablet twice a day.

For patients who have had a heart attack a year or more ago (but less than 2 years ago) and are at high risk of an atherothrombotic event, the dose of Brilique is one 60-mg tablet twice a day. Patients taking Brilique should also be taking aspirin as directed by their doctor. The doctor may, for health reasons, tell them not to take aspirin. For further information, see the package leaflet.

How does Brilique work?

The active substance in Brilique, ticagrelor, is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from forming. When the blood clots, this is due to cell fragments in the blood called platelets aggregating (sticking together). Ticagrelor stops the platelets aggregating by blocking the action of a substance called ADP when it attaches to the surface of the platelets. This stops the platelets becoming ‘sticky’, reducing the risk of a blood clot forming and helping to prevent a stroke or another heart attack.

How has Brilique been studied?

Brilique was compared with clopidogrel (another inhibitor of platelet aggregation) in a main study involving over 18,000 adults who had had a heart attack or had unstable angina. The patients also took aspirin and were treated for up to a year.

In another main study, Brilique was compared with placebo (a dummy treatment) in over 21,000 adults who had a heart attack one to three years previously and were at high risk of an atherothrombotic event. Patients took Brilique twice a day in a dose of either 60 mg or 90 mg. The patients also took aspirin and were treated for up to 3 years.

The main measure of effectiveness for both studies was based on the number of patients having another heart attack, a stroke or dying from a cardiovascular disease.

What benefit has Brilique shown during the studies?

Brilique was shown to be beneficial to patients who have had a heart attack or unstable angina. In the first main study (in patients with acute coronary syndrome), 9.3% of the patients taking Brilique had another heart attack, stroke or died from a cardiovascular disease compared with 10.9% of patients taking clopidogrel.

In the second main study (in patients with a history of the heart attack), 7.8% of patients taking Brilique 60 mg twice a day had another heart attack, stroke or died from cardiovascular disease compared with 9.0% of patients taking placebo.

What is the risk associated with Brilique?

The most common side effects with Brilique (seen in more than 1 patient in 10) are dyspnoea (difficulty breathing), bleeding and raised uric acid level in the blood. For the full list of all side effects reported with Brilique, see the package leaflet.

Brilique must not be used in patients who have severe liver disease or are currently bleeding, or in patients who have had bleeding within the brain. It must also not be used in patients taking other medicines which have a strong blocking effect on one of the liver enzymes (CYP3A4). These are medicines such as ketoconazole (used to treat fungal infections), clarithromycin (an antibiotic), atazanavir and ritonavir (medicines used in HIV-positive patients) and nefazodone (used to treat depression). For the full list of restrictions with Brilique, see the package leaflet.

Why has Brilique been approved?

The CHMP decided that Brilique’s benefits are greater than its risks and recommended that it be given marketing authorisation.

The CHMP considered that in patients with acute coronary artery syndrome, Brilique at a dose of 90 mg twice daily and given with aspirin, reduces the risk of atherothrombotic events such as heart attack, stroke and death from a cardiovascular event. Benefit regarding heart attack, stroke and death from a cardiovascular event has also been shown in patients who had a heart attack at least one year ago and have a high risk of an atherothrombotic event and a lower 60 mg dose twice daily dose is recommended for these patients.

Other information about Brilique

The European Commission granted a marketing authorisation valid throughout the European Union for Brilique on 3 December 2010.

For more information about treatment with Brilique, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Brilique : EPAR - Summary for the public BG = bălgarski 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public ES = español 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public CS = čeština 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public DA = dansk 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public DE = Deutsch 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public ET = eesti keel 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public EL = elliniká 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public EN = English 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public FR = français 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public IT = italiano 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public LV = latviešu valoda 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public LT = lietuvių kalba 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public HU = magyar 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public MT = Malti 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public NL = Nederlands 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public PL = polski 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public PT = português 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public RO = română 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public SK = slovenčina 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public SL = slovenščina 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public FI = suomi 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public SV = svenska 2011-01-07 2016-03-29
Brilique : EPAR - Summary for the public HR = Hrvatski 2011-01-07 2016-03-29

This EPAR was last updated on 19/10/2016 .

Authorisation details

Product details

Product details for Brilique
NameBrilique
Agency product numberEMEA/H/C/001241
Active substance

ticagrelor

International non-proprietary name (INN) or common name

ticagrelor

Therapeutic area Peripheral Vascular DiseasesAcute Coronary Syndrome
Anatomical therapeutic chemical (ATC) code B01AC24

Publication details

Publication details for Brilique
Marketing-authorisation holder

AstraZeneca AB

Revision9
Date of issue of marketing authorisation valid throughout the European Union03/12/2010

Contact address:

AstraZeneca AB
151 85 Södertälje
Sweden

Product information

Product information

15/09/2016  Brilique -EMEA/H/C/001241 -II/0033

Name Language First published Last updated
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19
Brilique : EPAR - Product Information HR = Hrvatski 2011-01-07 2016-10-19

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29
Brilique : EPAR - All Authorised presentations HR = Hrvatski 2011-01-07 2016-03-29

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with

  • acute coronary syndromes (ACS) or
  • a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event
  • Brilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.

    Assessment History

    Changes since initial authorisation of medicine

    Name Language First published Last updated
    Brilique : EPAR - Procedural steps taken and scientific information after authorisation HR = Hrvatski 2012-06-29 2016-10-19
    Brilique : EPAR - Assessment Report - Variation HR = Hrvatski 2016-03-29  

    Initial marketing-authorisation documents

    Name Language First published Last updated
    Brilique : EPAR - Public assessment report HR = Hrvatski 2011-01-07  
    CHMP summary of positive opinion for Brilique HR = Hrvatski 2010-09-24  

    Authorised

    This medicine is approved for use in the European Union